Squamous Cell Carcinoma of the Esophagus Completed Phase 2 Trials for Pralatrexate (DB06813)

IndicationStatusPhase
DBCOND0030042 (Squamous Cell Carcinoma of the Esophagus)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01129206Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based TherapyTreatment